Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SARNA Sensitive Lotion is a topical anti-itch formulation containing 1% pramoxine hydrochloride, a small molecule local anesthetic. Developed and studied by Wake Forest University specifically for the treatment of uremic pruritus in adult hemodialysis patients, the lotion works by stabilizing the neuronal membrane of local nerve endings in the skin, thereby inhibiting the initiation and conduction of nerve impulses to provide relief from itching. In a randomized, double-blind, controlled trial (NCT00693654), the pramoxine-based lotion demonstrated a 61% decrease in itch intensity compared to a bland emollient control. The 'Sensitive' formulation is specifically designed without menthol or camphor to be suitable for patients with sensitive or compromised skin, such as those undergoing hemodialysis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SARNA Sensitive Lotion.